SEC Form 4 · accession 0001189022-26-000004
CalciMedica, Inc. · CALC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert N Wilson
Director
Period of report
Aug 19, 2026
Accepted (ET)
Aug 21, 2026 · 6:42 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001534133
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantF2 | $0.8033 | Aug 19, 2026 | A | 1,182,621 | A | Aug 19, 2026 | Dec 25, 2027 | Common Stock | 1,182,621 | 1,182,621 | D |
| WarrantF3 | $1.00 | Aug 19, 2026 | A | 1,182,621 | A | Aug 19, 2026 | Jun 25, 2031 | Common Stock | 1,182,621 | 1,182,621 | D |
| Director Stock Option (Right to Buy)F4 | $0.6131 | Aug 19, 2026 | A | 10,000 | A | — | Aug 18, 2036 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
- F2The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.
- F3The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.
- F41/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.